Mayo Clinic Unveils New Treatment Pathways

What Are the New Treatment Pathways for Advanced Heart Failure?

Mayo Clinic's updated framework for advanced heart failure emphasizes earlier identification of patients whose disease is progressing despite guideline-directed medical therapy. Rather than waiting for repeated hospitalizations or cardiogenic shock, clinicians are encouraged to use validated risk markers — including declining functional capacity, intolerance of neurohormonal blockers, and rising natriuretic peptides — to trigger referral to advanced heart failure programs.

The pathways integrate four pillars of contemporary care: quadruple therapy with an ARNI or ACE inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor; device-based options such as cardiac resynchronization therapy and implantable defibrillators; durable left ventricular assist devices for selected patients; and timely heart transplant evaluation. The model is designed to ensure that no eligible patient progresses to end-stage disease without consideration of advanced therapies.

How Does Multidisciplinary Care Improve Outcomes in Advanced Heart Failure?

Advanced heart failure care benefits substantially from a team-based approach. According to the American Heart Association and European Society of Cardiology guidelines, multidisciplinary clinics that include heart failure cardiologists, cardiac surgeons, transplant coordinators, pharmacists, dietitians, and palliative care specialists are associated with fewer readmissions and better adherence to evidence-based therapy.

Mayo Clinic's pathway incorporates structured shared decision-making, particularly when discussing high-risk interventions such as LVAD implantation or transplant listing. Palliative care is introduced earlier in the disease trajectory rather than reserved for end-of-life, in line with recent professional society recommendations. This approach helps patients align treatment intensity with personal goals while maintaining access to advanced options as the disease evolves.

Who Should Be Referred for Advanced Heart Failure Evaluation?

The Heart Failure Society of America has long advocated using the I-NEED-HELP mnemonic to identify candidates for advanced heart failure referral: intravenous inotropes, NYHA class IIIB-IV symptoms, end-organ dysfunction, ejection fraction under 35%, defibrillator shocks, hospitalizations, edema despite escalating diuretics, low blood pressure, and progressive intolerance of guideline-directed medications.

Mayo Clinic's pathways operationalize these criteria into electronic health record prompts and standardized referral workflows. Earlier referral allows time for transplant work-up, frailty assessment, and shared decision-making — interventions that are often impossible to complete during an acute decompensation. The goal is to shift advanced heart failure care upstream, before patients become too sick to benefit from definitive therapies.